Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dorzagliatin.
- Who it may be relevant to
- Registry conditions: Diabetes Mellitus, Prediabetes / Type 2 Diabetes. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of Repeated Dose of Dorzagliatin on Insulin Secretion, Glucagon Release and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes
Overview
A total of 30 subjects will be recruited 15 with intermediate hyperglycemia and 15 in the tyep 2 diabetes group respectively. Eligible participants will undergo hyperglycemic-clamp/oral glucose tolerance at baseline and after 4 weeks of dorzagliatin treatment.
Interventions
- Drug Dorzagliatin
chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral)
Primary outcome measures
- Acute Insulin secretion [Time frame: At baseline and after 4 weeks of study drug treatment]
Secondary outcome measures (5)
- Second phase insulin secretion [Time frame: At baseline and after 4 weeks of study drug treatment]
- Beta cell glucose sensitivity [Time frame: At baseline and after 4 weeks of study drug treatment]
- Glucagon-like peptide -1 (GLP-1) [Time frame: At baseline and after 4 weeks of study drug treatment]
- Glucagon [Time frame: At baseline and after 4 weeks of study drug treatment]
- Incretin effect [Time frame: At baseline and after 4 weeks of study drug treatment]
Eligibility criteria
Inclusion criteria
- Individuals aged ≥ 18 years but < 70 years
- Male or female
- Body mass index of over 18 kg/m2 and < 35 kg/m2
Additional inclusion criteria for IH group
- Fasting plasma glucose <7.0 mmol/L and HbA1c < 6.5%
- 1 hour plasma glucose ≥8.6 and <11.6 mmol/L on 75g oral glucose tolerance test (OGTT)
- No use of glucose lowering drugs in past 6 months
Additional inclusion criteria for T2D group
- HbA1c 6.5 to 10% at screening
- On diet control, or stable dose of oral glucose lowering drugs metformin for at least 8 weeks
Exclusion criteria
- 1\. Subjects who do not agree to participate in this study. 2. Country of birth is unknown. 3. Body weight less than 45kg. 4. Acute phase of cerebrovascular and cardiovascular diseases (within 6 months of recruitment).
5\. Subjects with severe renal dysfunction as defined by eGFR <30 ml/min/1.73m2 or patients receiving renal dialysis (such as haemodialysis or continuous ambulatory peritoneal dialysis).
6\. Severe hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times upper limit of normal.
7\. Severe cardiovascular disease, history of stroke, heart failure (NYHA III or IV) or history of myocardial infarction within last 12 months.
8\. History of drug abuse or excessive alcohol intake based on investigator judgment.
9\. Dehydration, diarrhoea or vomiting at the time of recruitment. 10. Subjects with severe infection, in perioperative period or with serious injury at the time of recruitment.
11\. Subjects with anaemia (Haemoglobin <9.0mg/dL). 12. Pregnant or lactating or intending to become pregnant within 30 days after last dose of study drug.
13\. Participation in a clinical trial with investigational product within 30 days before enrolment.
14\. Donation or loss of blood (excluding the volume of blood that will be drawn during screening procedures) as follows: ≥300 mL of blood within 30 days prior to study drug administration.
15\. Subjects judged unsuitable for the study based on investigator judgment. 16. Use of strong or moderate CYP3A4 inhibitors or inducers and cannot be discontinued.
17\. Unwilling or unable to follow protocol requirements.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Hong Kong · 1 center
- Phase 1 Clinical Trial Centre — Hong Kong
Identifiers
NCT: NCT06671340 · SENSITISE-3